scholarly journals Successful stenting of left pulmonary veins stenosis resulting from fibrosing mediastinitis:

2015 ◽  
Vol 36 (39) ◽  
pp. 2623-2623
Author(s):  
Philippe Unger ◽  
Eric Stoupel ◽  
Rachid Briki ◽  
Vincent Ninane
2004 ◽  
Vol 61 (2) ◽  
Author(s):  
K. Malagari ◽  
S. Papiris

Idiopathic fibrosing mediastinitis is a rare entity involving more severely the more compliant structures within the mediastinum. In this report a rare case of simultaneous involvement of both the superior vena cava (SVC) and pulmonary veins is described in a 16 – year old male with progressive dyspnea on exertion, cough and a three months’ history of blood – tinged sputum. Physical examination and imaging studies revealed signs of pulmonary venous hypertension (PVH) and SVC stenosis. Fibrosing mediastinitis was confirmed by multiple biopsy samples.


2009 ◽  
Vol 88 (5) ◽  
pp. 1674-1676 ◽  
Author(s):  
Zeena Makhija ◽  
Francis Murgatroyd ◽  
Nicholas Gall ◽  
Michael T. Marrinan ◽  
Ranjit Deshpande ◽  
...  

Author(s):  
Juan J Portero-Portaz ◽  
Juan G Córdoba-Soriano ◽  
Arsenio Gallardo-López ◽  
Jesús M Jiménez-Mazuecos

Abstract Background pulmonary veins stenosis after atrial fibrillation radiofrequency ablation is an uncommon complication. When it occurs, percutaneous treatment is the preferred approach. There is a lack of standardized procedures, and when stenting restenosis is relatively common. Case summary we present a young patient with recurrence of pulmonary vein stenosis after a first percutaneous treatment. The recurrence of haemoptysis and dyspnoea after treatment in pulmonary vein stenosis allowed the diagnosis of significant stenosis again in our patient. In the Heart Team we opted for new percutaneous treatment, using IVUS to optimize the final result. Discussion nowadays, percutaneous approach is preferred and among percutaneous treatments for pulmonary veins stenosis, and stenting has shown better results than ballon angioplasty. Despite this, experience in instent restenosis is limited, and there is a lack of adequate and specific material for its approach. In this case we present the possible role of the IVUS and the drug-coated ballon angioplasty in this entity.


Author(s):  
W. K. Jones ◽  
J. Robbins

Two myosin heavy chains (MyHC) are expressed in the mammalian heart and are differentially regulated during development. In the mouse, the α-MyHC is expressed constitutively in the atrium. At birth, the β-MyHC is downregulated and replaced by the α-MyHC, which is the sole cardiac MyHC isoform in the adult heart. We have employed transgenic and gene-targeting methodologies to study the regulation of cardiac MyHC gene expression and the functional and developmental consequences of altered α-MyHC expression in the mouse.We previously characterized an α-MyHC promoter capable of driving tissue-specific and developmentally correct expression of a CAT (chloramphenicol acetyltransferase) marker in the mouse. Tissue surveys detected a small amount of CAT activity in the lung (Fig. 1a). The results of in situ hybridization analyses indicated that the pattern of CAT transcript in the adult heart (Fig. 1b, top panel) is the same as that of α-MyHC (Fig. 1b, lower panel). The α-MyHC gene is expressed in a layer of cardiac muscle (pulmonary myocardium) associated with the pulmonary veins (Fig. 1c). These studies extend our understanding of α-MyHC expression and delimit a third cardiac compartment.


Sign in / Sign up

Export Citation Format

Share Document